

## ASX Announcement

2 December 2024

### APPENDIX 3Y

**Melbourne, Australia, 2 December 2024:** Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company"), submits the Appendix 3Y of Dr Gregory Collier, Dr Ross Murdoch, and Mr Matthew McNamara.

#### For enquiries, please contact

Ms Melanie Leydin  
Company Secretary  
Avecho Biotechnology Limited  
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

#### About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (**TPM®**). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock.

See more here - [avecho.com.au](https://avecho.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b> Avecho Biotechnology Limited
<b>ABN</b> 32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Gregory Collier
<b>Date of last notice</b>	23 November 2023

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	29 November 2024
<b>No. of securities held prior to change</b>	<b>Direct</b> 5,990,465 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS) <b>Indirect</b> <i>Beacon Super Fund Pty Ltd &lt;Beacon Super Fund A/c&gt;</i> 1. 4,000,000 Fully Paid Ordinary Shares (AVE) 2. 3,000,000 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA) <i>Barwon Biotechnology Pty Ltd</i> 1. 5,833,333 Fully Paid Ordinary Shares (AVE) 2. 8,749,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS)
<b>Number acquired</b>	N/A
<b>Number disposed</b>	5,990,465
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<p><b>Indirect</b></p> <p><i>Beacon Super Fund Pty Ltd &lt;Beacon Super Fund A/c&gt;</i></p> <ol style="list-style-type: none"> <li>4,000,000 Fully Paid Ordinary Shares (AVE)</li> <li>3,000,000 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)</li> </ol> <p><i>Barwon Biotechnology Pty Ltd</i></p> <ol style="list-style-type: none"> <li>5,833,333 Fully Paid Ordinary Shares (AVE)</li> <li>8,749,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse and cancellation of options without being exercised.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Avecho Biotechnology Limited
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ross Murdoch
<b>Date of last notice</b>	10 May 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
<b>Date of change</b>	29 November 2024
<b>No. of securities held prior to change</b>	<b>Direct</b> 1. 3,993,644 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS) 2. 3,333,333 Fully Paid Ordinary Shares (AVE) 3. 2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)
<b>Class</b>	Unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS) (AVEAS)
<b>Number acquired</b>	N/A
<b>Number disposed</b>	3,993,644
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held after change</b>	<b>Direct</b> 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapse and cancellation of options without being exercised.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Avecho Biotechnology Limited
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Matthew Patrick McNamara
<b>Date of last notice</b>	23 November 2024

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	MLAKS PTY LIMITED <M & L MCNAMARA S/F A/C>  Mr McNamara is a director and shareholder of the entity. He is also a beneficiary of the super fund.
<b>Date of change</b>	29 November 2024
<b>No. of securities held prior to change</b>	<b>Indirect</b> MLAKS PTY LIMITED <M & L MCNAMARA SUPER A/C> <ul style="list-style-type: none"><li>3,993,644 unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS)</li><li>1,666,666 Fully Paid Ordinary Shares (AVE)</li><li>2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)</li></ul>
<b>Class</b>	Unlisted options exercisable at \$0.0169 each and expiring on 29 November 2024 (AVEAS)
<b>Number acquired</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	3,993,644
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
<b>No. of securities held after change</b>	<b>Indirect</b> <i>MLAKS PTY LIMITED &lt;M &amp; L MCNAMARA SUPER A/C&gt;</i> <ul style="list-style-type: none"> <li>• 1,666,666 Fully Paid Ordinary Shares (AVE)</li> <li>• 2,499,999 Quoted Options exercisable at \$0.012 each and expiring on 10 May 2026 (AVEOA)</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Lapse and cancellation of options without being exercised.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

For personal use only

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

For personal use only